Article thumbnail

Peptide inhibition of human cytomegalovirus infection

By Lilia I Melnik, Robert F Garry and Cindy A Morris
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1986). Alford CA: Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA
  2. (1991). Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment.
  3. (1999). Bertics PJ: Integrin-mediated migration of murine B82L fibroblasts is dependent on the expression of an intact epidermal growth factor receptor.
  4. (2009). Cannon MJ: A social marketing approach to building a behavioural intervention for congenital cytomegalovirus. Health Promot Pract
  5. (2007). Cannon MJ: Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol
  6. (1990). Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. AIDS
  7. (1980). Choppin PW: Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-terminal of the F1 or HA1 viral polypeptides. Virology
  8. (2008). Cobbs C: Platelet-derived growth factor-α receptor activation is required for human cytomegalovirus infection. Nature
  9. (1990). Compans RW: Oligopeptide inhibitors of HIV-induced syncytium formation. AIDS Res Hum Retroviruses
  10. (2002). Could an infectious trigger explain the differential maternal response to shared placental pathology of preeclampsia and normotensive intrauterine growth restriction? Acta Obstet Gynecol Scand
  11. (2009). CR: Multiple peptides homologous to Herpes Simplex Virus Type 1 glycoprotein B inhibit viral infection. Antimicrob Agents and Chemotherapy
  12. (2006). Crystal structure of the low- pH form of the vesicular stomatitis virus glycoprotein G. Science
  13. (1998). Curtain CC: Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion. AIDS Res Hum Retroviruses
  14. (2009). De Clercq E, Snoeck R: Drug targets in cytomegalovirus infection. Infectious disorders-drug targets
  15. (2002). Disulfide bond configuration of human cytomegalovirus glycoprotein B.
  16. (1992). E: Are fusion peptides really “sided” insertional helices? Cell
  17. (2006). Enfurvitide prevents vertical transmission of multidrugresistant HIV-1 in pregnancy but does not cross placenta. AIDS
  18. (2003). FDA approves Fuzeon, the first fusion inhibitor.
  19. (2003). Finberg RW: Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol
  20. (1986). GL: Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO
  21. (1993). Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology
  22. (1987). GS: The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. Anal Biochem
  23. (2003). Huang ES: Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature
  24. (2005). Huang ES: Integrin αvβ3 is a coreceptor for human cytomegalovirus. Nature Medicine
  25. (1996). Human cytomegalovirus cell tropism and pathogenesis. Intervirology
  26. (2009). Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread, but not for virion attachment, assembly, or egress.
  27. (2000). Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis.
  28. (2004). Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis
  29. (2008). I: The postfusion structure of baculovirus gp64 supports a unified view of viral fusion machines. Nat Struct Mol Biol
  30. (2009). Immunobiology of Human Cytomegalovirus: from Bench to Bedside. Clin Microbiol Rev
  31. (2004). JA: Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome.
  32. (1995). JA: Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis
  33. (2000). Kawaoka Y: Functional importance of the coiled-coil of the Ebola virus glycoprotein.
  34. (1996). KM: Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors.
  35. (1984). Kundsin RB: Placental evidence of cytomegalovirus infection of the fetus and neonate. Arch Pathol Lab Med
  36. (1995). L: Mutated forms of human cytomegalovirus glycoprotein B are impaired in inducing syncytium formation. Virology
  37. Mertens T: Antiviral intervention, resistance and perspectives. In Cytomegaloviruses Molecular biology and immunology. Edited by: Reddehase M.
  38. (1996). Petteway SR Jr: Peptides from conserved regions of paramoxovirus fusion (F) proteins are potent inhibitors of viral fusion.
  39. (2003). Radsak K: Differential effects of glycoprotein B epitope-specific antibodies on human cytomegalovirus-induced cell-cell fusion.
  40. (1996). Radsak K: Structural domains involved in human cytomegalovirus glycoprotein B-mediated cell-cell fusion.
  41. (2007). RF: Cytomegaloviruses. In Fields Virology. Volume 2. 5 edition. Edited by: Knipe
  42. (2006). RF: Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Research
  43. RF: Model of the pre-insertion region of the spike (S2) fusion glycoprotein of the human SARS coronavirus: implications for antiviral therapeutics.
  44. (2008). RF: Proteomics computational analyses suggest that baculovirus GP64 superfamily proteins are class III penetrenes. Virol J
  45. (1997). Ruoslahti E: Alphavbeta3 integrin associated with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO
  46. (2006). SC: Crystal structure of glycoprotein B from herpes simplex virus I. Science
  47. (2006). SF: Peptide inhibitors of dengue virus and west Nile virus infectivity. Virol J
  48. (2007). Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science
  49. (1993). T: A synthetic peptide from HIV-1 gp31 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses
  50. (1992). T: A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Nat Acad Sci USA
  51. (1999). TG: Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions.
  52. (2002). The PyMOL Molecular Graphics System.
  53. (2009). TS: Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Sci USA
  54. (1996). White SH: Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol
  55. (2010). WJ: Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirusimmune maternal population.